Table 5 Main features of post-vaccine headache described in available literature
Sekiguchi [15]a | Ekizoglu [113] | Göbel [121] | Göbel [53] | |
|---|---|---|---|---|
Subjects developing headache after vaccination against SARS-CoV-2 | 78 | 556 | 2349 | 2464 |
Females | n.r | 441 (79%) | 1289 (74%) | 1534 (85%) |
Age (mean ± SD) | n.r | 43.4 ± 12.3 | 41.0 ± 11.6 | 39.0 ± 12.7 |
Accompanying symptoms | ||||
Aggravation with activity | 49 (63%) | 137 (25%) | 1010 (43%) | 1232 (50%) |
Phonophobia | 16 (21%) | 83 (15%) | 658 (28%) | 813 (33%) |
Photophobia | 6 (8%) | 94 (17%) | 634 (27%) | 788 (32%) |
Nausea | 14 (18%) | 67 (12%) | 564 (24%) | 690 (28%) |
Osmophobia | n.r | 22 (4%) | 70 (3%) | 99 (4%) |
Headache severity | ||||
Mild | 126 (23%) | 328 (14%) | 267 (11%) | |
Moderate | 370 (66%) | 1081 (46%) | 867 (35%) | |
Severe | 60 (11%) | 940 (40%) | 1330 (54%) | |
NRSb | 5 (IQR: 4–8) | |||
Headache features | ||||
Unilateral location | 20 (26%) | 184 (33%) | 634 (27%) | 591 (24%) |
Pulsating quality | 39 (50%) | 223 (40%) | 681 (29%) | 838 (34%) |
Time to onset (hours; mean ± SD) | 12 (IQR: 7–18) | 43 ± 84 | 18 ± 27 | 15 ± 22 |
Duration (hours; mean ± SD) | 8 (IQR: 4–24) | 12 (IQR: 5–72) | 14 ± 21 | 16 ± 30 |
Need for drug use | 68 (87%) | 385 (70%) | 1396 (59%) | 1960 (80%) |